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Objective: Primary liver cancer (PLC) is a serious disease with high mortality. During the last 
decade, improvements in the diagnostic procedures and treatment of PLC may have improved 
survival. However, few updated longitudinal studies examined this issue. In a population-based 
setting, we studied changes in the prognoses over time.
Methods: Between 1998 and 2009, we identified all patients with PLC in the central and 
northern Denmark regions, with a combined population of 1.8 million. We determined age- and 
period-stratified survival, and computed mortality rate ratios (MRRs) with 95% confidence 
intervals (CIs), using Cox proportional hazard regression to assess changes over time, while 
controlling for age and gender. We conducted the analyses for PLC overall and separately for 
hepatocellular carcinoma (HCC) and cholangiocarcinoma, respectively.
Results: We included 1064 patients with PLC. Their median age was 69 years (range 17–94 
years). The number of patients diagnosed with PLC in the period 2007–2009 was approximately 
40% higher than the number in 1998–2000. One-year survival increased from 16% in 1998–2000 
to 28% in 2007–2009, corresponding to an adjusted 1-year MRR of 0.65 (95% CI: 0.54–0.79). 
In patients aged ,60 years, we found the most pronounced increase in 1-year survival, from 
14% to 49% in women and from 19% to 41% in men. The 3- and 5-year survival in the entire 
cohort increased from 5% to a predicted 11% and from 2% to a predicted 7% during our study 
period, respectively. Accordingly, the expected 3- and 5-year adjusted MRRs were 0.68 (95% 
CI: 0.57–0.82) and 0.68 (95% CI: 0.57–0.81), respectively. One-, 3-, and 5-year survival improved 
during the study period for both HCC and cholangiocarcinoma.
Conclusion: PLC survival remains poor in the Danish population, although we observed an 
increase over the period 1998–2009, particularly in young people.
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Introduction
Primary liver cancer (PLC) encompasses hepatocellular carcinoma, intrahepatic cho-
langiocarcinoma, and a few other rare histological types. PLC is the fifth most common 
cancer in the world and the third most common cause of cancer death worldwide. Yet, 
almost 85% of liver cancer cases occur in developing countries, and the incidence in 
men is more than two-fold higher than in women.1 In high-incidence parts of the world, 
chronic liver disease caused by persistent infection with hepatitis B or C viruses is 
the most common underlying cause, whereas alcohol-related liver diseases are more 
common in Denmark and other Nordic countries.2,3
During the last 20 years, diagnostic procedures like contrast-enhanced ultrasound, 
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introduced in order to detect PLC at an earlier stage.4,5 More 
advanced treatments, including surgical resection, minimal 
invasive ablation treatments, chemotherapy, and biological tar-
geted drugs have also become available in recent decades.6–9
Despite these efforts, survival remains very poor. 
A minimal improvement in 5-year survival was reported in 
the period 1964–2003 among PLC patients in the Nordic 
countries.2 However, among Nordic patients diagnosed in 
1999–2003, Danish patients had the lowest 5-year relative 
survival, 3% in men and 5% in women.2 A previous study 
from northern Denmark reported a median survival of PLC 
of 3 months in 2000–2004.10 Few other previous population-
based studies on PLC prognosis exist.
Therefore, we used the Danish National Patient Registry 
(DNPR) to examine changes in the 1-, 3-, and 5-year survival 
after PLC diagnosis in the 1998–2009 period.
Material and methods
We conducted this study in the central and the northern 
Denmark regions, with a combined population of 1.8 million 
persons. The National Health Service provides tax-supported 
health care for all inhabitants of Denmark, guaranteeing free 
access to hospitals. Virtually no PLC patients were treated 
in private hospitals during the study period.
Identification of primary liver cancer 
patients
Through the DNPR, we identified all patients who had a 
first-time hospitalization with PLC in the period January 1, 
1998 through December 31, 2009. The DNPR contains 
information about all admissions from nonpsychiatric hos-
pitals in Denmark since 1977.11 Outpatient and emergency 
room visits at hospitals have been included since 1995. This 
registry includes information on civil registration number, 
dates of admission and discharge, surgical procedure(s) per-
formed, and up to 20 diagnoses from each hospital contact. 
Diagnoses have been classified according to the International 
Classification of Diseases (ICD) 8th edition until the end 
of 1993 and 10th edition (ICD-10) thereafter. We included 
the following diagnoses: hepatocellular carcinoma (HCC) 
(ICD-10 code: C22.0), cholangiocarcinoma (ICD-10 code: 
C22.1), and other liver cancers (other specified carcinomas 
of liver: [ICD-10 code: C22.7] and unspecified malignant 
neoplasm of the liver [ICD-10 code: C22.9]).
Survival
Since 1968, the Central Office of Civil Registration has 
assigned a unique 10-digit personal identification   number 
to all Danish citizens.12 This number, unique to each 
  Danish resident, is used in all Danish registries, allow-
ing unambiguous individual-level data linkage. From the 
Civil   Registration System we also obtained information on 
vital status (dead or alive), date of death, and residence for 
all cancer patients.
Statistical analysis
We followed each patient from date of cancer diagnosis 
until emigration, death, or June 25, 2010, whichever came 
first. To visualize crude survival we constructed Kaplan–
Meier curves stratified according to period of diagnosis 
(1998–2000, 2001–2003, 2004–2006, and 2007–2009). We 
estimated 1-, 3-, and 5-year survival. In the latter periods, 
we estimated 3- and 5-year survival using a hybrid analysis 
in which we included the actual survival for as long as 
possible and then estimated the conditional probability of 
surviving thereafter based on the corresponding survival 
experience of patients in the previous periods (ie, using 
a period analysis technique).13 To compare mortality 
over time, we used Cox proportional hazards regression 
analysis with 1998–2000 as the reference period to esti-
mate 1-, 3-, and 5-year mortality rate ratios (MRRs) and 
corresponding 95% confidence intervals (CIs), adjust-
ing for age group and gender. We included age in three 
age groups (15–59 years, 60–79 years, and 80+). In two 
separate models, we additionally included age as a con-
tinuous variable and as a cubic spline curve with three 
knots, respectively. These models did not change our MRR   
estimates.
In an additional analysis, we stratified the patients by type 
of liver cancer in the four periods.
Analyses were performed using SAS version 9.2 (SAS 
Institute Inc, Cary, NC).
Results
Of the 1064 PLC patients diagnosed in the 1998–2009 period, 
39% were women. The median age at diagnosis was 69 years 
(range 17–94 years) (Table 1 and Figure 1).
The annual number of PLC patients increased during 
the study period, from 225 patients diagnosed in 1998–2000 
to 316 diagnosed in the period 2007–2009. This increase 
covered a 10% increase in patients aged 15–59 years at PLC 
diagnosis, a 48% increase in the group aged 60–79, and a 
75% increase in patients aged 80 years or older. Among 
patients aged 60–79, the increase was mainly seen among 
men (Table 2), while the increase in patients aged more than 
80 years was mainly seen in women (Table 3).Clinical Epidemiology 2011:3 (Suppl 1) submit your manuscript | www.dovepress.com
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The 1-year survival improved from 16% (1998–2000) to 
28% (2007–2009). Accordingly, the 1-year crude MRR was 
0.67 (95% CI 0.55–0.82) in 2007–2009, using 1998–2000 
as reference. Adjustment for age and sex did not change the 
MRR substantially (Table 1 and Figure 2).
The largest increase in 1-year survival was seen in patients 
aged 15–59 years (Tables 2 and 3). The 3-year survival 
improved from 5% in 1998–2000 to about 10% in the other 
periods. The crude MRR declined to 0.85 (95% CI 0.71–1.02) 
in 2004–2006, while the estimated crude MRR in the 2007–
2009 period was 0.69 (95% CI 0.58–0.83). Again, the adjust-
ments did not notably change the results. The 5-year survival 
improved from 2% (1998–2000) to estimated 7% (2007–2009) 
over the study period corresponding to a 2007–2009 crude 
MRR of 0.69 (95% CI 0.58–0.82) (Table 1).
Table 4 shows the distribution of the type of PLC during 
the study periods.
Survival improved both in patients with HCC and in 
those with cholangiocarcinoma during the study period 
(Tables 5 and 6). Among HCC patients, 1-, 3-, and 5-year 
survival increased from 24% to 37%, from 5% to estimated 
12% and from 3% to estimated 9%, respectively, in the 
period 2007–2009, compared with 1998–2000. The crude 
and adjusted MRRs showed a corresponding decrease in the 
mortality of about 30% in the period 2007–2009 relative to 
the period 1998–2000 (Table 5).
Among patients with cholangiocarcinoma 1-, 3-, and 
5-year survival increased from 19% to 27%, from 3% to 
estimated 11% and from 0% to estimated 4%, respec-
tively (Table 6). The crude and adjusted MRRs showed a 
Table 1 Survival and MRRs with 95% confidence intervals according to year of primary liver cancer diagnosis, central and northern 
Denmark 1998–2009
Year of diagnosis
1998–2000 2001–2003 2004–2006 2007–2009
number of cancer patients 225 255 268 316
Median age (years) 68 69 68 69
1 year
Survival 16% (12%–22%) 22% (17%–28%) 21% (16%–26%) 28% (23%–34%)
Mrr 1 (reference) 0.83 (0.68–1.01) 0.86 (0.71–1.05) 0.67 (0.55–0.82)
Adjusted Mrra 1 (reference) 0.83 (0.68–1.01) 0.87 (0.71–1.05) 0.65 (0.54–0.79)
3 year
Survival 5% (3%–9%) 12% (9%–16%) 9% (6%–13%) 11% (8%–15%)b
Mrr 1 (reference) 0.79 (0.65–0.95) 0.85 (0.71–1.02) 0.69 (0.58–0.83)b
Adjusted Mrra 1 (reference) 0.79 (0.66–0.96) 0.85 (0.71–1.03) 0.68 (0.57–0.82)b
5 year
Survival 2% (1%–4%) 6% (3%–9%) 6% (4%–9%)b 7% (4%–11%)b
Mrr 1 (reference) 0.79 (0.66–0.95) 0.83 (0.69–0.99)b 0.69 (0.58–0.82)b
Adjusted Mrra 1 (reference) 0.79 (0.66–0.95) 0.83 (0.70–1.00)b 0.68 (0.57–0.81)b
Notes: aadjusted for age and gender; bpredicted values.
Abbreviation: Mrr, mortality rate ratio.
0
16 20 24 28 32 36 40 44 48 52 56 60 64 68 72 76 80 84 88 92 96 100
2
4
6
10
8
12
0
2
4
6
10
8
12
P
e
r
c
e
n
t
P
e
r
c
e
n
t
W
o
m
e
n
M
e
n
Figure 1 The age distribution of men and women at primary liver cancer diagnosis, central and northern Denmark 1998–2009.Clinical Epidemiology 2011:3 (Suppl 1) submit your manuscript | www.dovepress.com
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additional 5 years and, moreover, by calculating the estimated 
3- and 5-year survival for patients diagnosed in the most 
recent years. We affirmed that while the survival continued to 
increase in Denmark, it is still poor compared with that in other 
developed   countries. The latest EUROCARE report (which 
did not include PLC data from Denmark), covering the period 
2000–2002, reported 1-, 5-, and 10-year relative survival rates 
for PLC of 33.5%, 9.8%, and 6.3%, respectively.14 Similar 
results were reported in the United States with 5-year relative 
survival rates of 8.3% in the period 1995–2000.15 Recent data 
on PLC prognosis in other settings confirm improvement of 
Table 3 Survival and 95% confidence intervals in women with primary liver cancer, according to age and year of diagnosis, central and 
northern Denmark 1998–2009
Women Year of diagnosis
Age (years) 1998–2000 2001–2003 2004–2006 2007–2009
15–59
number of cancer patients 21 23 28 27
1-year survival 14% (4%–32%) 35% (17%–54%) 43% (25%–60%) 49% (29%–67%)
3-year survival 10% (2%–26%) 26% (11%–45%) 29% (14%–46%) 20% (8%–37%)a
5-year survival 0% 26% (11%–45%) 21% (9%–38%)a 14% (5%–28%)a
60–79
number of cancer patients 59 60 46 66
1-year survival 15% (8%–26%) 17% (9%–27%) 33% (20%–46%) 21% (12%–31%)
3-year survival 3% (1%–10%) 5% (1%–13%) 15% (7%–27%) 6% (2%–13%)a
5-year survival 2% (0%–8%) 3% (1%–10%) 12% (5%–24%)a 5% (2%–12%)a
80+
number of cancer patients 12 25 16 30
1-year survival 8% (1%–31%) 12% (3%–28%) 13% (2%–33%) 13% (4%–28%)
3-year survival 0% 4% (0%–17%) 0% –
5-year survival 0% 0% 0% –
Note: apredicted values.
Table 2 Survival and 95% confidence intervals in men with primary liver cancer, according to age and year of diagnosis, central and 
northern Denmark 1998–2009
Men Year of diagnosis
Age (years) 1998–2000 2001–2003 2004–2006 2007–2009
15–59
number of cancer patients 42 49 45 42
1-year survival 19% (9%–32%) 29% (17%–41%) 22% (11%–35%) 41% (26%–56%)
3-year survival 7% (2%–17%) 18% (9%–30%) 11% (4%–22%) 24% (12%–39%)a
5-year survival 2% (0%–11%) 6% (2%–15%) 9% (3%–19%)a 20% (9%–35%)a
60–79
number of cancer patients 75 82 114 132
1-year survival 19% (11%–28%) 27% (18%–37%) 12% (7%–19%) 27% (19%–35%)
3-year survival 7% (2%–14%) 15% (8%–23%) 3% (1%–7%) 9% (4%–16%)a
5-year survival 3% (1%–8%) 5% (2%–11%) 0%a –
80+
number of cancer patients 16 16 19 19
1-year survival 13% (2%–33%) 0% 16% (4%–35%) 32% (13%–52%)
3-year survival 0% 0% 5% (0%–21%) 6% (0%–25%)a
5-year survival 0% 0% – –
Note: apredicted values.
  corresponding decrease in mortality a little below 30% in 
the period 2007–2009 relative to 1998–2000, although the 
CIs are rather wide.
Discussion
In this population-based study the 1-, 3-, and 5-year mor-
tality decreased approximately 30% among PLC patients 
between 1998 and 2009. Still, their life expectancy remained 
poor.
The results from this present study extend the findings 
from a previous study by our group10 by adding data from an Clinical Epidemiology 2011:3 (Suppl 1) submit your manuscript | www.dovepress.com
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survival during the last decades, although their results vary 
for country, sex, and age group,2,16,17 whereas others focus 
entirely on hepatocellular carcinoma or consider previous 
time periods.18–20
Our study design had both strengths and limitations. The 
study was large, population-based, with a well defined primary 
catchment area, complete registration, and long-term follow-up. 
Thus, selection bias was negligible. Nevertheless, the quality 
of the diagnosis coding in the DNPR is crucial. In a previous 
publication, we compared the PLC survival from the DNPR to 
that from the Danish Cancer Registry (DCR), which is almost 
100% complete and valid,21 and found similar results.22 More-
over, in two other studies from our region, the completeness of 
both ovarian cancer diagnosis and prostate cancer diagnosis in 
the DNPR compared with the DCR were 96%, and the positive 
predictive values were among 95% and 97%.23,24
Although the overall quality of the PLC diagnosis in the 
DNPR was found to be good, the quality of specific types 
of PLC diagnoses was poorer. Indeed, approximately 40% 
of the patients had an unspecified type of liver cancer. Since 
HCC accounts for approximately 85% of primary liver 
cancer worldwide,25 the possibility of HCC coded as “other 
liver cancers” is more than plausible. Nevertheless, patients 
coded with HCC and cholangiocarcinoma are likely to have 
these diseases (ie, high positive predictive value), and we 
therefore believe that our survival estimates for these sub-
groups are valid.
Another limitation is our lack of data on cancer stage and 
treatment. Furthermore, information on alcohol consumption, 
coexistence of liver cirrhosis and hepatitis virus infection, and 
other comorbidities were not available. Changes over time 
in these factors could have provided further evidence of the 
underlying reason for the observed improvement in survival.
One of the possible explanations, at least among patients 
with hepatocellular carcinoma, of the poorer survival in 
Denmark compared with the other developed countries could 
be related to the high prevalence of cirrhosis due to alcohol 
abuse in Denmark.26,27 In fact, unlike several other Western 
countries where immigration from developing areas with 
endemic hepatitis B and spread of hepatitis C are suggested 
to play a major role in PLC developing, the hepatitis C 
  prevalence in Denmark is approximately 0.3%, and it has 
remained low during the study period while alcoholism 
remained the most frequent cause of cirrhosis.28,29
0
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Figure 2 Survival curves for patients with primary liver cancer according to year of diagnosis, central and northern Denmark 1998–2009.
Table 4 Distribution of liver cancer types in the different study 
periods in central and northern Denmark 1998–2009
Type of liver cancer
Year 
diagnosis
HCC 
(%)
Cholangiocarcinoma 
(%)
Other 
(%)
Total
1998–2000 79 (35.1%) 31 (13.8%) 115 (52.1%) 225
2001–2003 103 (40.4%) 41 (16.1%) 111 (43.5%) 255
2004–2006 114 (42.5%) 50 (18.7%) 104 (38.8%) 268
2007–2009 151 (47.8%) 58 (18.4%) 107 (33.8%) 316
Total 447 (42.0%) 180 (16.9%) 437 (41.1%) 1064
Notes: Other liver cancers include unspecified liver cancers as well as specified types 
other than hCC and cholangiocarcinoma. 
Abbreviation: hCC, hepatocellular carcinoma.Clinical Epidemiology 2011:3 (Suppl 1) submit your manuscript | www.dovepress.com
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Alcohol abuse may have strong negative impact on PLC 
survival for two main reasons. First, among patients with 
alcohol abuse, liver cirrhosis is almost always present at 
the time of hepatocellular carcinoma diagnosis, which is 
not the case in patients with hepatitis C-related hepatic 
cancer.30 Since liver cirrhosis is known to be associated 
with poor prognosis,26 patients with hepatitis C related 
PLC probably have a better survival after resection. Second, 
chronic alcohol abuse in itself is known to increase both 
overall mortality among cirrhotic patients31 and postop-
erative mortality in the general population.32 Alcoholic 
liver cirrhosis with severe compromised liver function is 
therefore often considered a contraindication for surgical 
resection for liver cancer.33 Moreover, we found the larg-
est survival improvement among patients <60 years, and 
Jepsen et al reported that alcoholic cirrhosis prevalence 
and incidence in the Danish population have decreased in 
people <45 years from 1996 to 2005 and have only slightly 
increased in people aged 45–64 years in the same period.34 
This evidence could support the hypothesis that alcohol 
abuse could be related to the higher mortality among 
patients with HCC.
Table 5 Survival and 95% confidence intervals in patients with hepatocellular carcinoma, according to age and year of diagnosis, central 
and northern Denmark 1998–2009
Year of diagnosis
1998–2000 2001–2003 2004–2006 2007–2009
number of cancer patients 79 103 114 151
Median age (years) 67 68 66 69
1 year
Survival 24% (15%–34%) 28% (20%–37%) 22% (15%–30%) 37% (29%–45%)
Mrr 1 (reference) 0.94 (0.67–1.33) 1.05 (0.76–1.45) 0.67 (0.49–0.93)
Adjusted Mrra 1 (reference) 0.93 (0.66–1.31) 1.04 (0.75–1.45) 0.65 (0.47–0.91)
3 year
Survival 5% (2%–11%) 17% (11%–25%) 9% (4%–15%) 12% (7%–19%)b
Mrr 1 (reference) 0.81 (0.59–1.10) 0.97 (0.72–1.31) 0.71 (0.53–0.94)b
Adjusted Mrra 1 (reference) 0.80 (0.59–1.09) 0.97 (0.72–1.31) 0.70 (0.52–0.93)b
5 year
Survival 3% (0%–8%) 7% (3%–13%) 6% (3%–12%)b 9% (5%–16%)b
Mrr 1 (reference) 0.84 (0.62–1.14) 0.96 (0.72–1.29)b 0.70 (0.53–0.93)b
Adjusted Mrra 1 (reference) 0.83 (0.61–1.13) 0.95 (0.71–1.27)b 0.69 (0.52–0.92)b
Notes: aadjusted for age and gender; bpredicted values.
Abbreviation: Mrr, mortality rate ratio.
Table 6 Survival and 95% confidence intervals in patients with cholangiocarcinoma, according to age and year of diagnosis, central and 
northern Denmark 1998–2009
Year of diagnosis
1998–2000 2001–2003 2004–2006 2007–2009
number of cancer patients 31 41 50 58
Median age (years) 64 68 69 67
1 year
Survival 19% (8%–35%) 22% (11%–35%) 24% (13%–36%) 27% (16%–39%)
Mrr 1 (reference) 0.87 (0.52–1.47) 0.82 (0.50–1.37) 0.74 (0.45–1.22)
Adjusted Mrra 1 (reference) 0.91 (0.54–1.56) 0.84 (0.51–1.39) 0.73 (0.44–1.20)
3 year
Survival 3% (0%–14%) 5% (1%–15%) 8% (3%–18%) 11% (4%–20%)b
Mrr 1 (reference) 0.86 (0.54–1.39) 0.79 (0.50–1.26) 0.73 (0.46–1.15)b
Adjusted Mrra 1 (reference) 0.88 (0.53–1.43) 0.79 (0.49–1.25) 0.72 (0.46–1.15)b
5 year
Survival 0% (0%–14%) 2% (0%–11%) 3% (0%–11%)b 4% (0%–14%)b
Mrr 1 (reference) 0.83 (0.52–1.34) 0.76 (0.48–1.21)b 0.70 (0.45–1.10)b
Adjusted Mrra 1 (reference) 0.88 (0.53–1.47) 0.74 (0.47–1.18)b 0.70 (0.44–1.10)b
Notes: aadjusted for age and gender; bpredicted values.
Abbreviation: Mrr, mortality rate ratio.Clinical Epidemiology 2011:3 (Suppl 1) submit your manuscript | www.dovepress.com
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Several factors may explain the improved prognosis of 
PLC patients reported in our study. Recent advances in sur-
gical and medical therapy such as radio-frequency ablation, 
stereotactic radiotherapy, biological targeted therapy, and 
chemo-embolization could lead to improved survival.35–37 In 
addition, better diagnostic tests including radiology and serol-
ogy have the potential for detecting PLC at an earlier stage 
and thereby increasing the likelihood of effective treatment.4,5 
However, earlier diagnosis of PLC owing to increased accuracy 
of diagnostic tests may result in prolonged survival, even with-
out any prognostic changes (ie, lead time bias), and we cannot 
exclude that this could partly explain our results.   Nonetheless, 
the median age at diagnosis did not decrease during the study 
period, providing some evidence that the improvement in 
survival was not caused solely by earlier diagnosis.
In conclusion, in Denmark, PLC survival increased over 
the study period, but it still remains poor.
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